# Erasca, Inc.: financial statements, quarterly

ERAS · Nasdaq · CIK 1761918 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eras.md) · [Financials](/companies/eras/financials.md) · [Filings](/companies/eras/filings.md) · [Insiders](/companies/eras/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eras/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating income | $m | [(34.7)](/filings/0000950170-24-125481.md) | [(33.9) d](/filings/0000950170-25-042682.md) | [(38.9)](/filings/0000950170-25-070418.md) | [(67.8)](/filings/0001193125-25-178996.md) | [(37.2)](/filings/0001193125-25-277625.md) | [(35.7) d](/filings/0001193125-26-104150.md) | [(35.6)](/filings/0001193125-26-216788.md) | [(38.1)](/filings/0001193125-26-344611.md) | [(34.5)](/filings/0001193125-25-277625.md) | [(32.6) d](/filings/0001193125-26-104150.md) | [(188)](/filings/0001193125-26-216788.md) | [(47.6)](/filings/0001193125-26-344611.md) |
| Net income | $m | [(30.4)](/filings/0000950170-24-125481.md) | [(29.7) d](/filings/0000950170-25-042682.md) | [(35.0)](/filings/0001193125-25-277625.md) | [(63.2)](/filings/0001193125-25-277625.md) | [(31.2)](/filings/0001193125-25-277625.md) | [(32.2) d](/filings/0001193125-26-104150.md) | [(31.0)](/filings/0001193125-26-344611.md) | [(33.9)](/filings/0001193125-26-344611.md) | [(30.6)](/filings/0001193125-25-277625.md) | [(29.1) d](/filings/0001193125-26-104150.md) | [(183)](/filings/0001193125-26-344611.md) | [(44.1)](/filings/0001193125-26-344611.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0000950170-24-125481.md) | not reported | [(0.23)](/filings/0000950170-25-070418.md) | [(0.29)](/filings/0001193125-25-178996.md) | [(0.11)](/filings/0001193125-25-277625.md) | not reported | [(0.11)](/filings/0001193125-26-216788.md) | [(0.12)](/filings/0001193125-26-344611.md) | [(0.11)](/filings/0001193125-25-277625.md) | not reported | [(0.60)](/filings/0001193125-26-216788.md) | [(0.14)](/filings/0001193125-26-344611.md) |
| Basic EPS | $ per share | [(0.20)](/filings/0000950170-24-125481.md) | not reported | [(0.23)](/filings/0000950170-25-070418.md) | [(0.29)](/filings/0001193125-25-178996.md) | [(0.11)](/filings/0001193125-25-277625.md) | not reported | [(0.11)](/filings/0001193125-26-216788.md) | [(0.12)](/filings/0001193125-26-344611.md) | [(0.11)](/filings/0001193125-25-277625.md) | not reported | [(0.60)](/filings/0001193125-26-216788.md) | [(0.14)](/filings/0001193125-26-344611.md) |

- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [113](/filings/0000950170-24-125481.md) | [93.1](/filings/0000950170-25-042682.md) | [173](/filings/0001193125-25-178996.md) | [173](/filings/0000950170-24-095437.md) | [68.9](/filings/0001193125-25-277625.md) | [67.7](/filings/0001193125-26-104150.md) | [70.5](/filings/0001193125-26-216788.md) | [66.1](/filings/0001193125-26-344611.md) | [70.2](/filings/0001193125-25-277625.md) | [73.8](/filings/0001193125-26-344611.md) | [47.3](/filings/0001193125-26-216788.md) | [42.5](/filings/0001193125-26-344611.md) |
| Current assets | $m | [306](/filings/0000950170-23-062094.md) | [321](/filings/0000950170-25-042682.md) | [307](/filings/0000950170-24-055668.md) | [418](/filings/0000950170-24-095437.md) | [330](/filings/0000950170-24-125481.md) | [309](/filings/0001193125-26-104150.md) | [315](/filings/0000950170-25-070418.md) | [311](/filings/0001193125-25-178996.md) | [300](/filings/0001193125-25-277625.md) | [286](/filings/0001193125-26-344611.md) | [254](/filings/0001193125-26-216788.md) | [278](/filings/0001193125-26-344611.md) |
| Total assets | $m | [419](/filings/0000950170-23-062094.md) | [395](/filings/0000950170-25-042682.md) | [370](/filings/0000950170-24-055668.md) | [526](/filings/0000950170-24-095437.md) | [529](/filings/0000950170-24-125481.md) | [503](/filings/0001193125-26-104150.md) | [471](/filings/0000950170-25-070418.md) | [445](/filings/0001193125-25-178996.md) | [420](/filings/0001193125-25-277625.md) | [396](/filings/0001193125-26-344611.md) | [461](/filings/0001193125-26-216788.md) | [435](/filings/0001193125-26-344611.md) |
| Current liabilities | $m | [26.7](/filings/0000950170-23-062094.md) | [26.2](/filings/0000950170-25-042682.md) | [30.2](/filings/0000950170-24-055668.md) | [24.9](/filings/0000950170-24-095437.md) | [30.0](/filings/0000950170-24-125481.md) | [31.4](/filings/0001193125-26-104150.md) | [25.5](/filings/0000950170-25-070418.md) | [28.2](/filings/0001193125-25-178996.md) | [28.7](/filings/0001193125-25-277625.md) | [28.5](/filings/0001193125-26-344611.md) | [26.7](/filings/0001193125-26-216788.md) | [33.6](/filings/0001193125-26-344611.md) |
| Total liabilities | $m | [80.4](/filings/0000950170-23-062094.md) | [78.6](/filings/0000950170-25-042682.md) | [81.6](/filings/0000950170-24-055668.md) | [74.7](/filings/0000950170-24-095437.md) | [78.9](/filings/0000950170-24-125481.md) | [79.0](/filings/0001193125-26-104150.md) | [71.7](/filings/0000950170-25-070418.md) | [73.1](/filings/0001193125-25-178996.md) | [72.5](/filings/0001193125-25-277625.md) | [71.0](/filings/0001193125-26-344611.md) | [67.7](/filings/0001193125-26-216788.md) | [73.2](/filings/0001193125-26-344611.md) |
| Shareholders' equity | $m | [339](/filings/0000950170-24-125481.md) | [317](/filings/0001193125-26-104150.md) | [288](/filings/0001193125-25-277625.md) | [451](/filings/0001193125-25-277625.md) | [450](/filings/0001193125-25-277625.md) | [423](/filings/0001193125-26-344611.md) | [400](/filings/0001193125-26-344611.md) | [372](/filings/0001193125-26-344611.md) | [348](/filings/0001193125-25-277625.md) | [325](/filings/0001193125-26-344611.md) | [394](/filings/0001193125-26-344611.md) | [362](/filings/0001193125-26-344611.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(24.1) d](/filings/0000950170-24-125481.md) | [(24.8) d](/filings/0000950170-25-042682.md) | [(33.3)](/filings/0000950170-25-070418.md) | [(29.2) d](/filings/0001193125-25-178996.md) | [(22.4) d](/filings/0001193125-25-277625.md) | [(24.6) d](/filings/0001193125-26-104150.md) | [(31.6)](/filings/0001193125-26-216788.md) | [(20.5) d](/filings/0001193125-26-344611.md) | [(21.7) d](/filings/0001193125-25-277625.md) | [(21.7) d](/filings/0001193125-26-104150.md) | [(27.4)](/filings/0001193125-26-216788.md) | [(27.3) d](/filings/0001193125-26-344611.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000950170-24-125481.md) | [0.1 d](/filings/0000950170-25-042682.md) | [0.0](/filings/0000950170-25-070418.md) | [0.0 d](/filings/0001193125-25-178996.md) | [0.0 d](/filings/0001193125-25-277625.md) | [0.0 d](/filings/0001193125-26-104150.md) | [0.1](/filings/0001193125-26-216788.md) | [0.0 d](/filings/0001193125-26-344611.md) | [0.0 d](/filings/0001193125-25-277625.md) | [0.0 d](/filings/0001193125-26-104150.md) | [0.0](/filings/0001193125-26-216788.md) | [0.0 d](/filings/0001193125-26-344611.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [121](/filings/0000950170-23-062094.md) | [150](/filings/0000950170-24-055668.md) | [150](/filings/0000950170-24-095437.md) | [150](/filings/0000950170-24-125481.md) | [151](/filings/0000950170-25-070418.md) | [218](/filings/0001193125-25-178996.md) | [282](/filings/0001193125-25-277625.md) | [283](/filings/0001193125-26-216788.md) | [283](/filings/0001193125-26-344611.md) | [284](/filings/0001193125-25-277625.md) | [304](/filings/0001193125-26-216788.md) | [311](/filings/0001193125-26-344611.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 349,762,035 at 2026-08-04, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344611.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.